Observational studyThe Journal of clinical endocrinology and metabolism2018
Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study.
Observational study in The Journal of clinical endocrinology and metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 86 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Influence of Continuous Glucose Monitoring on Quality of Life in People With Type 2 Diabetes Mellitus
Mitigating Diabetic Ketoacidosis in People With T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation Into an Enhanced Glucose Ketone Report
Who cites it
86 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- Effect of Different Glucose Monitoring Methods on Bold Glucose Control: A Systematic Review and Meta-Analysis.Computational and mathematical methods in medicine · 2022Pooled it
- Green Line Hospital-Territory Study: A Single-Blind Randomized Clinical Trial for Evaluation of Technological Challenges of Continuous Wireless Monitoring in Internal Medicine, Preliminary Results.International journal of environmental research and public health · 2021Trial
- Engineered MspA Nanopores for Real-Time Detection of Insulin, Its Pharmaceutical Analogues, and Degradation Products.ACS nano · 2026Article
- Weight and HbA1c trajectories following initiation of continuous glucose monitoring in adults with type 1 diabetes: a cohort study using group-based multi-trajectory analysis.The Lancet regional health. Europe · 2026Article
- Managing Gestational Diabetes Complexity with Continuous Glucose Monitoring: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- A consensus statement on a National Competency Framework for training and assessment of knowledge and skills in diabetes technologies, including hybrid closed loop (HCL), insulin pump systems, and continuous glucose monitoring (CGM) devices.Diabetic medicine : a journal of the British Diabetic Association · 2026Article
- Trends in use of continuous glucose monitors among individuals with type 2 diabetes enrolled in Medicare Advantage (2021-2023).Journal of managed care & specialty pharmacy · 2026Article
- Continuous glucose monitoring, diabetes distress, and well-being in adults with type 1 diabetes: findings from a National Survey in Lithuania.Frontiers in clinical diabetes and healthcare · 2026Article
- Glucose monitoring, support systems, and motivating factors among individuals newly diagnosed with type 2 diabetes: an explorative study in the Upper East Region, Ghana.BMC public health · 2025Article
- How do hypoglycaemias affect the everyday life of people with diabetes and are they able to treat them adequately?Diabetic medicine : a journal of the British Diabetic Association · 2025Article
- Satisfaction with life in young adults with type 1 diabetes mellitus.Scientific reports · 2025Article
- Evaluation of glycemia risk index and continuous glucose monitoring-derived metrics in type 1 diabetes: a real-world observational study.Journal of diabetes and metabolic disorders · 2025Article
- The Role of Remote Glucose Management Using Real-time Continuous Glucose Monitoring Systems in ICU-hospitalized Patients with COVID-19.TouchREVIEWS in endocrinology · 2025Review
- Glucose metrics and device satisfaction in adults with type 1 diabetes using different treatment modalities: a multicenter, real-world observational study.Acta diabetologica · 2025Observational
- Advances in Continuous Glucose Monitoring: Clinical Applications.Endocrinology and metabolism (Seoul, Korea) · 2025Review
- The role of advanced technologies in improving diabetes outcomes.The American journal of managed care · 2025Review
- Dynamic Interference Testing-Unexpected Results Obtained with the Abbott Libre 2 and Dexcom G6 Continuous Glucose Monitoring Devices.Sensors (Basel, Switzerland) · 2025Article
- Health-Economic Modelling of Improved Behavior in Insulin Injection Technique in Belgium.PharmacoEconomics - open · 2025Article
- Persistent Performance Improvement Using Team Resources and Continuous Glucose Monitoring in Patients With Poorly Controlled Type 2 Diabetes.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Randomized controlled trials evaluating real-time continuous glucose monitoring (RT-CGM) patients with type 1 diabetes (T1D) show improved glycemic control, but limited data are available on real-world use. Objective: To assess impact of RT-CGM in real-world settings on glycemic control, hospital admissions, work absenteeism, and quality of life (QOL). Design: Prospective, observational, multicenter, cohort study. Participants: A total of 515 adults with T1D on continuous subcutaneous insulin infusion (CSII) therapy starting in the Belgian RT-CGM reimbursement program. Intervention: Initiation of RT-CGM reimbursement. Main Outcome Measure: Hemoglobin A1c (HbA1c) evolution from baseline to 12 months. Results: Between September 1, 2014, and December 31, 2016, 515 adults entered the reimbursement system. Over this period, 417 (81%) patients used RT-CGM for at least 12 months. Baseline HbA1c was 7.7 ± 0.9% (61 ± 9.8 mmol/mol) and decreased to 7.4 ± 0.8% (57 ± 8.7 mmol/mol) at 12 months (P < 0.0001). Subjects who started RT-CGM because of insufficient glycemic control showed stronger decrease in HbA1c at 4, 8, and 12 months compared with patients who started because of hypoglycemia or pregnancy. In the year preceding reimbursement, 16% of patients were hospitalized for severe hypoglycemia or ketoacidosis in contrast to 4% (P < 0.0005) the following year, with decrease in admission days from 54 to 18 per 100 patient years (P < 0.0005). In the same period, work absenteeism decreased and QOL improved significantly, with strong decline in fear of hypoglycemia. Conclusion: Sensor-augmented pump therapy in patients with T1D followed in specialized centers improves HbA1c, fear of hypoglycemia, and QOL, whereas work absenteeism and admissions for acute diabetes complications decreased.
Indexed as
Identifiers
29342264What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.